The Effect of 20 mg Hyoscine Butylbromide on Normal Labor in Iraqi Primi- and Multi-gravida Women

Abstract

The objective of the current study was to determine whether hyoscinebutylbromide (HBB) shortens first stage of labor in both primi- and multigravida women. A prospective, double blinded, controlled clinical trial carried out in Al-Elwiya Maternity Teaching Hospital, from January to December 2009; 200 primi- and multigravidae were allocated into two groups, the HBB, received 20mg HBB and control group, received 1.0ml of normal saline intravenously once they enter the active phase of labor. Duration of the active phase of the first stage was monitored in addition to comparison with second and third stages, rate of caesarean section, Apgar score and neonatal admission to neonatal intensive care unit. HBB shortens the first stage of labor only in primigravidae, with no differences in duration of second and third stages, rate of caesarean section. There was a significant difference in Apgar score at 1.0 min between HBB and control groups in primigravidae, with no increase in the rate of neonatal admission to the neonatal intensive care unit and adverse effects. HBB significantly decreases duration of the first stage of labor only in multigravida women, and not associated with any obvious adverse outcomes on mothers and neonates.